Cargando…

Correction to: Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640391/ https://www.ncbi.nlm.nih.gov/pubmed/38021034 http://dx.doi.org/10.1093/jacamr/dlad121

Ejemplares similares

Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin
por: Merchante, Nicolás, et al.
Publicado: (2023)

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection
por: Zhang, Kevin, et al.
Publicado: (2021)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis
por: Chiu, Chia-Yu, et al.
Publicado: (2019)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

2565. Initial and Recurrent Episodes of Clostridioides difficile: Online Education as a Tool to Improve Management Strategies
por: Hurst, Simi Thomas, et al.
Publicado: (2019)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

Author Correction: Entry of spores into intestinal epithelial cells contributes to recurrence of Clostridioides difficile infection
por: Castro-Córdova, Pablo, et al.
Publicado: (2022)

680. Comparison of Extended Duration Vancomycin Regimens for Clostridioides difficile Infection in Patients on Prolonged Antibiotic Courses
por: Garzia, Christopher, et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
por: Bromilow, Tom, et al.
Publicado: (2023)

The Clinical Efficacy, Safety, and Tolerability of Vancomycin for the Treatment of Recurrent Clostridioides difficile Infection – A Systematic Review
por: Knudsen, Maja Johanne Søndergaard, et al.
Publicado: (2023)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

Correction to: An emergent infectious disease: Clostridioides difficile infection hospitalizations, 10-year trend in Sicily
por: Medaglia, Alice Annalisa, et al.
Publicado: (2021)

Correction for Paulick et al., “Characterization of Clostridioides difficile Isolates Available through the CDC & FDA Antibiotic Resistance Isolate Bank”
por: Paulick, Ashley, et al.
Publicado: (2022)

Frontiers in antibiotic alternatives for Clostridioides difficile infection
por: Phanchana, Matthew, et al.
Publicado: (2021)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice
por: Tomkovich, Sarah, et al.
Publicado: (2020)

2412. Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side-effects: Two Hospitals Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

Correction: Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
Publicado: (2014)

Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
por: Maraolo, Alberto Enrico, et al.
Publicado: (2022)

Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile
por: Rahmoun, Layan Abu, et al.
Publicado: (2021)

Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis
por: Muhammad, Aziz, et al.
Publicado: (2020)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

Uncovering the Harms of Treating Clostridioides difficile Colonization
por: Polage, Christopher R., et al.
Publicado: (2021)

Risk of antibiotics associated with Clostridioides difficile infection: Antibiotic stewardship in action
por: Dysangco, Andrew T., et al.
Publicado: (2022)

High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates
por: Tijerina-Rodríguez, Laura, et al.
Publicado: (2019)

Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study
por: Umemura, Takumi, et al.
Publicado: (2019)

Author Correction: Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection
por: Ferar, Kathleen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d1amm45263ua47letlpomstfhc